IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

IGC Pharma (NYSE American: IGC) activated a new site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's dementia at Tandem Clinical Research in Metairie, Louisiana.

Rhea-AI Summary

IGC Pharma (NYSE American: IGC) activated a new site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's dementia at Tandem Clinical Research in Metairie, Louisiana.

Principal Investigator Dr. Angela Traylor will lead the site. Enrollment is reported as over 70% complete, and the addition aims to expand geographic reach and patient access.

Positive

• Enrollment >70% complete in the Phase 2 CALMA trial
• New investigational site in Metairie, LA expands geographic reach
• Experienced PI Dr. Angela Traylor added to trial leadership

Negative

• None.

Argus Apr 7 session

+0.90% close to close Open Argus

Details

News Market Reaction – IGC

On Apr 7, the day this news came out, IGC closed 0.90% above the previous close.

Data tracked by StockTitan Argus for the Apr 7 session.

Market Context

This announcement adds an experienced Tandem Clinical Research site to the Phase 2 CALMA trial, with...

Analysis

This announcement adds an experienced Tandem Clinical Research site to the Phase 2 CALMA trial, with enrollment reported above 70%. It extends the trial’s geographic reach and investigator base as IGC advances IGC-AD1 for Alzheimer’s-related agitation. In context with prior site additions and IP protections, the news underscores steady operational progress. Investors may watch for enrollment completion, database lock, topline results, and any further use of the existing resale registration.

Key Figures

CALMA enrollment: >70% of planned patients

CALMA enrollment

>70% of planned patients

Phase 2 CALMA trial enrollment status at time of site addition

Previous Clinical trial Reports

5 past events · Latest: Feb 23

Same Type 5 events

1. Feb 23

   Site added to CALMA

   24h Move

   +2.2%

   Added Visionary Investigators Network site as CALMA approached 70% enrollment.

2. Feb 17

   IP and trial progress

   24h Move

   +0.0%

   Secured North American composition protection for IGC-AD1 as CALMA neared 70% enrollment.

3. Feb 09

   CALMA expansion abroad

   24h Move

   +1.2%

   Expanded CALMA into Colombia, growing to 23 active sites and ~70% enrollment.

4. Feb 02

   70% enrollment update

   24h Move

   +1.5%

   Reported reaching ~70% enrollment with ~23 sites and mid-2026 completion goal.

5. Jan 22

   New CALMA site NY

   24h Move

   +7.3%

   Added Integrative Clinical Trials in Brooklyn to strengthen CALMA execution and data quality.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 2, clinical trial, principal investigator, alzheimer's disease

4 terms

phase 2 medical

"ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

clinical trial medical

"ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

principal investigator technical

"is led by Principal Investigator Dr. Angela Traylor"

A principal investigator is the lead person responsible for overseeing a research project or study, ensuring it stays on track and meets its goals. In the context of investments, this role can be likened to the person in charge of a team or initiative, making key decisions and managing resources. Understanding who the principal investigator is can help investors assess the reliability and credibility of a project or research effort.

alzheimer's disease medical

"developing innovative treatments for Alzheimer's disease"

A progressive brain disorder that slowly erodes memory, thinking and the ability to carry out daily tasks as nerve cells are damaged and lost; symptoms typically worsen over years and can lead to severe impairment. Investors care because it drives a large, growing market for diagnostics, treatments and care services, but also carries high scientific, regulatory and commercial risk—similar to developing a complex new product that must pass difficult safety tests before it can reach patients.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

POTOMAC, MD / ACCESS Newswire / April 7, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing innovative treatments for Alzheimer's disease, today announced the activation of a new clinical trial site at Tandem Clinical Research A Prolerity Network Site in Metairie, Louisiana, for the Company's ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation in Alzheimer's dementia.

The site, located at 3901 Houma Blvd., Suite 500, Metairie, LA 70006, is led by Principal Investigator Dr. Angela Traylor, an experienced neurologist and psychiatrist who has served as both Principal Investigator and Sub-Investigator across multiple neurology and mental-health clinical studies. She will be supported by a seasoned Clinical Trial Coordination team with extensive experience in patient engagement and clinical-operations management.

"We are pleased to welcome Tandem Clinical Research as a new clinical partner in the CALMA trial," said Ram Mukunda, CEO of IGC Pharma. "With enrollment now over 70% complete, expanding to this highly qualified investigational site with strong neurological expertise strengthens the trial's geographic reach, and enhances patient access. We look forward to working closely with Dr. Traylor and her team."

About IGC Pharma (dba IGC):

IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.

Forward-Looking Statements:

This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Contact Information:

Walter Frank / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IGC Pharma announce about the CALMA trial on April 7, 2026 (IGC)?

IGC activated a new Phase 2 CALMA trial site in Metairie, Louisiana to support IGC-AD1 enrollment. According to IGC Pharma, this site addition aims to broaden geographic reach and improve patient access as enrollment surpasses 70%.

How far along is enrollment in the CALMA trial for IGC-AD1 (IGC)?

Enrollment in the Phase 2 CALMA trial is reported as over 70% complete. According to IGC Pharma, adding the Tandem Clinical Research site is intended to accelerate remaining enrollment and enhance participant access.

Who is the principal investigator at the new IGC CALMA trial site (IGC)?

Dr. Angela Traylor will serve as principal investigator at the Metairie site. According to IGC Pharma, Dr. Traylor is an experienced neurologist and psychiatrist with prior roles as principal investigator and sub-investigator in neurology studies.

Where is the new CALMA trial site for IGC-AD1 located (IGC)?

The new site is at 3901 Houma Blvd., Suite 500, Metairie, LA 70006, operated by Tandem Clinical Research. According to IGC Pharma, the site strengthens regional patient access and clinical operations support for the CALMA trial.

What impact does the Tandem Clinical Research site have on IGC's CALMA trial timeline (IGC)?

The site addition is intended to support remaining patient enrollment and broaden trial reach. According to IGC Pharma, expanding to a qualified investigational site should enhance recruitment efficiency as the study exceeds 70% enrollment.

Will the new Metairie site change the CALMA trial's leadership or operations (IGC)?

The Metairie site adds Dr. Angela Traylor and a seasoned clinical coordination team to trial operations. According to IGC Pharma, this brings additional neurological and patient-engagement expertise to support CALMA trial conduct.